Novavax Inc (NASDAQ: NVAX)
$9.5900
-1.2300 ( -8.41% ) 5.1M
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Market Data
Open
$9.5900
Previous close
$10.8200
Volume
5.1M
Market cap
$1.57B
Day range
$9.4810 - $11.4000
52 week range
$3.5324 - $23.8599
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 11, 2024 |
4 | Insider transactions | 1 | Mar 11, 2024 |
4 | Insider transactions | 1 | Mar 11, 2024 |
4 | Insider transactions | 1 | Mar 05, 2024 |
10-k | Annual reports | 128 | Feb 28, 2024 |
8-k | 8K-related | 16 | Feb 28, 2024 |
8-k | 8K-related | 14 | Feb 22, 2024 |
8-k | 8K-related | 14 | Jan 31, 2024 |